ALTSTATION.IO

Boston Scientific Corporation (BSX) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$76.26

Change

-1.80%

Market Cap

$113.07B

Avg Volume

12.1M

Company Overview

Boston Scientific Corporation (BSX) develops and sells medical devices used in various interventional specialties. Their product lineup includes devices for gastrointestinal, urological, neurological, and cardiovascular conditions, such as stents, catheters, and implantable cardiac monitors. Hospitals and healthcare providers are their primary customers, relying on BSX for advanced technologies that aid in diagnosis and treatment.

Boston Scientific is a key player in the medical device market, often positioned as a market leader in several segments. They compete against major companies like Medtronic and Abbott, facing threats from rapid innovation and regulatory changes. Their extensive research and development efforts, along with a broad product portfolio, give them a competitive edge. However, pressure on pricing and reimbursement policies can challenge their market position.

Currently, Boston Scientific is in a growth phase. The company recently announced plans to expand its cardiac and urology product lines, reflecting a strategic focus on high-growth areas. Their recent acquisition of a company specializing in endoscopic procedures further strengthens their portfolio. Revenue for Q2 2023 was reported at $3.2 billion, a 10% increase year-over-year, showcasing their solid performance amidst a competitive landscape.

Key Financials

Market Cap

$113.07B

Revenue

$20.07B

EBITDA

$5.60B

Gross Margin

70.2%

Profit Margin

14.4%

Revenue Growth

15.9%

Total Cash

$1.28B

Total Debt

$12.04B

Free Cash Flow

N/A

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

39.30

Forward P/E

19.43

Beta

0.66

52-Week High

$109.50

52-Week Low

$74.86

EPS

$1.94

50-Day Avg

$94.34

200-Day Avg

$100.31

Price/Book

4.83

Technical Analysis

Over the past 52 weeks, Boston Scientific Corporation (BSX) has exhibited a clear downtrend, with the stock price decreasing from approximately $110 to its current level of $76.26, indicating a decline of 28.2%. Key resistance is noted at the $100 level, which has acted as a ceiling on several occasions, while support appears in the $75 area, where the price is currently testing. The chart displays a significant lower high formation, particularly in January and February. Recently, BSX has shown negative momentum, particularly in the last few weeks with a steep decline, suggesting a bearish sentiment among investors. Currently, the stock is sitting near its 52-week low range, which implies potential downside risk if support fails to hold, but also presents a possible buying opportunity if a reversal occurs at this level.

Recent News and Developments

Market Update

Here’s a summary of the latest news and developments for Boston Scientific Corporation (BSX) stock in the past week (February 1-7, 2026):

Market Update

### Boston Scientific Reports Strong Q4 2025 Earnings, But Disappoints with 2026 Guidance

Market Update

Boston Scientific announced its fourth-quarter and full-year 2025 financial results on February 4, 2026. The company reported strong Q4 net sales of $5.286 billion, an increase of 15.9% year-over-year, and adjusted earnings per share (EPS) of $0.80, surpassing analyst estimates. However, the positive Q4 performance was overshadowed by a cautious 2026 outlook, with the company’s guidance for adjust

Market Sentiment and Analyst Recommendations

Bull Case

Boston Scientific just grew revenue 15.9% year-over-year with Q4 net sales of $5.286 billion, and beat EPS estimates at $0.80. The company is a dominant player in medical devices across cardiology, oncology, and endoscopy — markets with structural tailwinds from aging populations and rising procedure volumes. At 39.3x P/E, the valuation looks expensive on the surface, but 32 analysts maintain strong buy ratings with a median target of $107.75, implying 41% upside from current levels. The $1.28 billion in cash against $12.04 billion debt is manageable for a $113 billion market cap company generating $20 billion in revenue. If BSX executes even 10.5% net sales growth in 2026 as guided, and the market stops punishing the stock for not beating expectations, you’re looking at a $100+ stock within 12 months.

Bear Case

The 17.6% stock collapse on February 4th wasn’t random — it was a direct response to BSX guiding for 10.5-11.5% growth in 2026, a sharp deceleration from 15.9% in 2025. That’s not confidence, that’s the company admitting the easy growth is behind them. The electrophysiology division specifically disappointed, which is a core profit driver. The stock is down 28.2% from its 52-week high of $109.50, and now faces a securities fraud investigation related to the earnings miss, adding legal risk and uncertainty. At a 39.3x P/E ratio on decelerating growth, BSX is pricing in perfection while delivering slowdown. The $75 support level is real — if it breaks, there’s no clear floor until $65-70.

What to Watch

Monitor the securities investigation closely. If it escalates into actual charges or material settlements, the stock could crater further. Watch Q1 2026 results in late April for early signs whether guidance was conservative or optimistic — electrophysiology trends specifically matter here. Track the $100 resistance level; a sustained break above it would signal the market is ready to move past the guidance miss. Keep an eye on procedure volume data from hospitals and ASCs in cardiology and oncology, since BSX’s growth depends entirely on procedure volume recovery and adoption of their newer devices. If management raises 2026 guidance at any point, that’s a major bullish signal. Conversely, if they lower guidance again, the stock tests $65-70 quickly.

Analyst Consensus

STRONG BUY

Based on 32 analyst opinions

Low Target

$90.00

Mean Target

$107.75

High Target

$130.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Devices

Employees

N/A

Earnings & Dividends

Next Earnings

Apr 22, 2026

EPS (Trailing)

$1.94

Dividend Yield

None

Payout Ratio

Frequently Asked Questions

Is BSX a good stock to buy?

Yes, Boston Scientific (BSX) is recommended as a STRONG BUY with a target price of $107.75. The company’s solid position in the healthcare sector and its robust growth potential make it an attractive investment.

What is BSX’s price target?

Analysts have set a target price of $107.75 for Boston Scientific. This suggests an upside of approximately 41.4% from the current price of $76.26.

Does BSX pay a dividend?

No, Boston Scientific does not currently pay a dividend. This is typical for growth-oriented companies that prefer to reinvest profits into expansion rather than distribute them to shareholders.

What is BSX’s P/E ratio?

Boston Scientific has a P/E ratio of 39.30 and a forward P/E of 19.43. This indicates that while the stock is currently priced at a premium, future earnings growth potential could justify this valuation.

What has been BSX’s stock performance over the past year?

Boston Scientific’s stock has traded between $74.86 and $109.50 over the last 52 weeks. While it faced some volatility, the long-term outlook remains promising.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.